129 related articles for article (PubMed ID: 37879366)
1. Letter to the Editor Re: Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial.
Frugé AD; Smith KS; Crowder SL; Demark-Wahnefried W
J Natl Compr Canc Netw; 2023 Oct; 21(10):xxiii.a-xxiv.a. PubMed ID: 37879366
[No Abstract] [Full Text] [Related]
2. Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial.
Lanser DAC; de Leeuw SP; Oomen-de Hoop E; de Bruijn P; Paats MS; Dumoulin DW; Koolen SLW; Dingemans AC; Mathijssen RHJ; Veerman GDM
J Natl Compr Canc Netw; 2023 Jun; 21(6):645-651.e1. PubMed ID: 37308124
[TBL] [Abstract][Full Text] [Related]
3. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Morcos PN; Parrott N; Banken L; Timpe C; Lindenberg M; Guerini E; Dall G; Bogman K; Sturm C; Zeaiter A; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):266-279. PubMed ID: 27545871
[TBL] [Abstract][Full Text] [Related]
5. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
Sacdalan DB; Lucero JA
Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
[TBL] [Abstract][Full Text] [Related]
6. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
[TBL] [Abstract][Full Text] [Related]
7. Alectinib for ALK-positive non-small-cell lung cancer.
Rossi A
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
[TBL] [Abstract][Full Text] [Related]
8. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zeng Q; Zhang X; He S; Zhou Z; Xia L; Zhang W; Zeng L
Chemotherapy; 2022; 67(2):67-80. PubMed ID: 34915469
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
Sivignon M; Monnier R; Tehard B; Roze S
PLoS One; 2020; 15(1):e0226196. PubMed ID: 31945065
[TBL] [Abstract][Full Text] [Related]
11. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Morcos PN; Bogman K; Hubeaux S; Sturm-Pellanda C; Ruf T; Bordogna W; Golding S; Zeaiter A; Abt M; Balas B
Cancer Chemother Pharmacol; 2017 Mar; 79(3):559-568. PubMed ID: 28243683
[TBL] [Abstract][Full Text] [Related]
12. Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China".
Guan H; Sheng Y; Guo W; Han S; Shi L
Adv Ther; 2020 Feb; 37(2):971-972. PubMed ID: 31902064
[No Abstract] [Full Text] [Related]
13. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
15. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report.
Park JE; Yoon YR; Kim CH; Lee J
Thorac Cancer; 2022 Apr; 13(8):1224-1226. PubMed ID: 35191596
[TBL] [Abstract][Full Text] [Related]
17. Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K; Hida T; Nokihara H; Morise M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Yoshimoto T; Takata S; Tamura T
ESMO Open; 2022 Aug; 7(4):100527. PubMed ID: 35843080
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
[TBL] [Abstract][Full Text] [Related]
20. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
